Abstract:2654 Background: Immune checkpoint inhibitors are revolutionizing cancer care and providing new treatment options with promising outcomes for many cancers. However, immune-related adverse events (irAEs) are not infrequent and can be severe. An intriguing relationship between the presence of irAEs and treatment efficacy has been described but lacks thorough characterization. We aimed to further elucidate a relationship between immune checkpoint inhibitor (ICI) irAEs and efficacy. Methods: We identified cancer patients treated with ICI from 2015-2021 across two institutions: Michael E DeBakey Veterans Affairs Medical Center (MEDVAMC) and Baylor St. Luke’s Medical Center (BSLMC). Clinical data including cancer type, irAEs type and grade, ICI response, progression free survival (PFS) and overall survival (OS) was collected. Using the Kaplan Meier method, survival curves were generated and comparisons were made amongst groups using the log-rank test. Fisher’s exact test was used to compare progression of disease between groups. To determine if variables were associated with survival, multivariable Cox regression analysis was used. Results: Of the 456 patients treated with ICI, irAEs were seen in 165 (36%) patients. Of these, 81 (49%) patients had grade 1 toxicities, most commonly arthritis, diarrhea, and dermatitis. 47 (28%) patients had grade 2 toxicities (colitis, hypothyroidism, adrenal insufficiency). 34 (21%) patients had grade 3 toxicities (pneumonitis, pancreatitis, hepatitis). 3 patients had grade 4 toxicities (pneumonitis, DRESS syndrome, and hepatorenal syndrome). 1 patient expired and 24 (15%) patients discontinued ICI due to irAEs. 55 (33%) of patients with irAEs were treated with steroids. For patients assessed for efficacy, objective response rate (ORR) to ICI was higher in patients with irAEs [47% (12% CR) vs 33% (11% CR)]. In fact, the presence of any irAEs was significantly likely to predict response to ICI (OR 1.90, 95% CI 1.25 - 2.86, p = 0.0026). In a subset of patients evaluable for survival (n = 375), patients with any irAEs had a significantly improved median PFS compared to those without irAEs (9.0 vs. 4.8 months, p = 0.0018). Multivariable analysis demonstrated that the development of any irAEs was related to a significantly improved OS (HR 0.63, 95% CI 0.43-0.89, p = 0.01). Conclusions: The development of irAEs in cancer patients treated with immunotherapy may predict better treatment efficacy and overall survival. Further prospective studies are needed to confirm these associations and mechanism of action.

Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers

Incidence, Morphology and Clinical Relevance of Bony Canals and Vascular Grooves in the Paracondylar Region of Adult Human Skulls

Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review

Oral immune-related adverse events caused by immune checkpoint inhibitors: a retrospective study

Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma

Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors

Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study

Oral mucosal toxicities induced by immune checkpoint inhibitors: Clinical features and algorithm management

Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review

Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases

Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer

Predictors for the Development of Neurological Immune-Related Adverse Events of Immune Checkpoint Inhibitors and Impact on Mortality

Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.

Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer

Mucocutaneous adverse events to immune checkpoint inhibitors

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System

Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors

Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department

Immune Checkpoint Inhibitor-Associated Ophthalmic Adverse Events: Current Understanding of Its Mechanisms, Diagnosis, and Management